Canadian Blood Services and its independent Research Ethics Board (REB) review all studies involving human participants conducted by or on behalf of Canadian Blood Services, including studies involving personal information (data) or biologic materials (products) collected by Canadian Blood Services.
Investigators must submit an application to have their studies approved. The review process includes the following steps:
Step 1: Approval by Canadian Blood Services.
Step 2: Approval by Canadian Blood Services REB, if required. The REB has three scheduled meetings per year (in early June, October, and March). Additional reviews can be organized throughout the year, as needed.
Step 3: Execution of an agreement between Canadian Blood Services and the Principal Investigator/Organization, if required.
The decision to approve a study depends on the information provided in the application. Investigators must share any new knowledge that changes this information with Canadian Blood Services through an amendment. Investigators must also inform Canadian Blood Services of incidental findings and privacy breaches.
WHAT WOULD YOU LIKE TO DO?
Submit a new application
Investigators must complete one Part A and one or more Part B, depending on the nature of the application. Review the Application Guidelines and the Application Forms for details. Contact CBSREB@blood.ca for assistance.
Investigators are required to notify Canadian Blood Services of any modifications to their approved studies. Modifications must first be approved by Canadian Blood Services and its independent REB, if required, before changes can be implemented unless subject safety is at risk. Modifications include, but are not limited to, changes to Principal Investigator, co-Investigator(s), or primary contact.
Canadian Blood Services approvals are granted for a period of one year and must be renewed on an annual basis. A maximum of four renewals may be granted (i.e., for an overall study period of five years).
Investigators are required to immediately report to Canadian Blood Services all serious adverse events occurring to a research participant enrolled in their studies. Incidental findings and minor adverse events must be reported within seven days.